As the proportion of senior citizens increases in Western industrialized societies, there is a need to identify older adults with first signs of limited mobility to delay the onset of mobility disability and subsequent loss of autonomy through the implementation of adequate intervention programmes. According to Newfield et al., 1 mobility limitation is defined as a state of impaired mobility, a condition in which a person experiences a limitation in independent physical movement or is at risk of experiencing limitations. As a result of the rather broad definition of mobility limitation, prevalence rates range from 20 to 50% for adults aged !65 years. 2, 3 The likelihood of mobility limitation increases in elderly people with cardiovascular risk factors (e.g. hypertension, obesity or diabetes) and/or disease (e.g. ischaemic heart disease, atrial fibrillation, heart failure and stroke). 4 The Centers for Disease Control and Prevention reported that 41% of senior citizens aged !60 years with diagnosed diabetes had mobility limitations compared with 29% for their agematched peers with no diagnosis of diabetes. 5 Given the high prevalence of elderly patients with diagnosed cardiovascular disease and mobility limitations and because of the importance of mobility to healthy ageing and quality of life, it is timely and imperative to implement adequate test instruments in clinical settings. Previous research (for a review, see Yeom et al. 6 ) has identified a number of intrapersonal (e.g. advanced age, female sex, sedentary lifestyle, overweight and low socioeconomic status), interpersonal (e.g. low social participation and overprotection from care-giver), physiological (e.g. sarcopenia, dynapenia, low cardiac output and vitamin D deficiency) and environmental risk factors (e.g. a lack of a stimulating environment and a restricted access to services such as grocery stores) that are associated with the development of mobility limitation in senior citizens. These multi-dimensional factors are the reason why clinicians and researchers apply a large variety of single tests (e.g. the Timed Up and Go Test, the Gait Speed Test (GST), the 6-min Walk Distance Test (6MWT) and the Handgrip Strength Test), test batteries (e.g. the Short Physical Performance Test Battery, the Berg Balance Test and the Tinetti Test) and self-reported psychometric tests (e.g. Life-Space Assessment and MobilityHelp) in daily practice for mobility assessment (for a review, see Chung et al. 7 ). To avoid ceiling or floor effects, the respective tests have to be selected according to age, fitness status, cognitive function and existing comorbidities. The use of test batteries is time consuming and requires extensive test equipment, which is why this test modality is often not feasible in daily clinical routines. Therefore reliable and valid single tests are needed that are sensitive enough to detect mobility limitations in healthy seniors and seniors with diagnosed disease.
The 6MWT and the GST are frequently applied as single tests in clinical settings for the identification of older adults with mobility limitations. Both tests have been proved to be reliable and valid in different population and patient groups. [8] [9] [10] [11] [12] [13] For the assessment of the 6MWT, it is recommended to perform the test in a large room along the perimeter of a 12 Â 9 m area demarked with four cones. Observers should provide the following instructions: 'Walk at your normal pace for six minutes on the outside of the four cones. The test will determine the distance you cover in six minutes'.
14 Participants perform one test trial only. An observer times the six minutes with a stopwatch and measures the distance covered in metres. 15 A distance <350 m is associated with increased mortality in chronic obstructive pulmonary disease, chronic heart failure and pulmonary arterial hypertension. 16 During the performance of the GST, the test room should be well-lit and quiet. It is recommended that participants walk with their own footwear at selfselected speeds, initiating and terminating each walk a minimum of 2 m before and after the 10 m straight and even walkway to allow sufficient distance to accelerate to and decelerate from a steady-state of ambulation across the walkway. The following instruction should be given: 'Walk at your normal pace along the 14 -m walkway. The test will determine the time it takes you to cover a 10 m distance'. The observer starts the stopwatch as soon as the patient's limb crosses the first marker of the 10 m walkway and stops the stopwatch as soon as the patient's limb crosses the second marker. 17 Only one test trial is conducted. In frail older adults, it is recommended to attach a safety belt around the participant's waist so that the observer can easily grab the belt in case of a fall. 18 Gait speed (m/s) is computed by dividing the walking distance (m) by the time (s) it takes to walk 10 m. Older adults who walk at a preferred speed of <0.8 m/s have greater risks for impaired mobility, activity of daily living disability and even early mortality. 17, 19 Safety issues in terms of a quick access to emergency medicine have to be considered for both tests, but particularly for the metabolically more demanding 6MWT. 20 In this issue of the European Journal of Preventive Cardiology Kamiya et al. 21 directly compared the prognostic capability of the 6 MWT and GST in 1474 patients (mean age 72.2 AE 7.1 years; 68% men) with cardiovascular disease -predominantly heart failure (38.5%), cardiac surgery (26.5%) and acute coronary syndrome (21.7%) -who were referred to cardiac rehabilitation between 2008 and 2015. Data on medical variables were retrieved from electronic records. During a mean follow up of 2.3 AE 1.9 years, a total of 180 deaths occurred.
The two tests, performed on the same day at hospital discharge, were positively correlated (r ¼ 0.80). Gait speed also showed a high discriminate performance for the prediction of 6MWT <300 and 400 m, (AUC 0.93, 95% CI 0.91-0.94 for <300 m; AUC 0.90, 95% CI 0.88-0.91 for 400 m), with sensitivity and specificity values both >80%. Consequently, the prognostic predictive capability of the 6MWT and the GST for allcause mortality using ROC analysis were comparable (0.66, 95% CI 0.61-0.70 for the 6MWT and 0.64, 95% CI 0.60-0.69 for gait speed) and showed a closeresponse association with mortality in an inverse Jshaped manner, i.e. an increased risk of mortality with decreasing values in both tests.
The findings from this study have clinical implications in cardiac rehabilitation. With the ageing of society and the development of new technically interventions -for example, transcatheter aortic valve replacement -it is of paramount important to implement mobility as a measure of dynapenia/sarcopenia/ frailty to offer different training strategies focusing on muscle strength, coordination and balance in these patient populations. 22 Several studies have indicated that the single GST outperforms other multicomponent frailty scales and shows comparable prognostic capabilities to those of the 6MWT. 23, 24 Gait speed therefore appears to be a simple screening tool for most rehabilitation settings.
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